Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc.

BaseSpace Informatics Suite

Illumina For Startups

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Oxford Nanopore Technologies

SomaLogic

Twist Bioscience

GenoLogics

Ginkgo Bioworks

Grail

Helixis

Bank of America

Lombard Odier

Chase Capital Partners

Chevron Technology Ventures

ARCH Venture Partners

State Farm

Tredegar Investments

Venrock

CW Group

Illumina

The "chewing gum," made from birch bark pitch and saliva, likely served as glue for tools. Researchers analyzed the #DNA in the gum, revealing the Stone Age teenagers' diet, including deer, trout, apple, duck, fox, and hazelnuts.

May the Year of the Dragon bring you joy, prosperity, and good luck! 🐲 

In 2023, we launched a novel technology to help reach the darkest corners of the genome and make long-read sequencing accessible. Now, we have built upon Illumina Complete Long Read technology with a new highly accurate, targeted long-read solution—compatible with predesigned and fully custom panels—offering greater flexibility for long-read sequencing.
 
Why? To help scientists access more of the genome and find answers to improve human health.

Learn more about Illumina Complete Long Read Prep with Enrichment:
https://bit.ly/3Oliav7


Good things come in threes, and the lineup of #NovaSeqX flow cells are no different. The addition of the 1.5B flow cell to the reagent kit portfolio provides unmatched flexibility to take on smaller batch or pilot projects. 

Scale up your way with the NovaSeq X Series: https://bit.ly/3u8LlKS

NASDAQ:ILMN

Illumina Inc

Last Close

124.46

24/04 20:00

Market Cap

22.33B

Beta: 1.18

Volume Today

1.25M

Avg: 1.23M

PE Ratio

−19.97

PFCF: 133.64

Share Trends

Transaction Log

Please Sign In To Use The Chat